Joanne Lagmay, M.D.
Associate Professor; STOP Children's Cancer Of Palm Beach County, Inc. Professorship In Pediatric Oncology
About Joanne Lagmay
Joanne Lagmay, M.D., is board-certified in general pediatrics and pediatric hematology/oncology. Her main focus has been the multidisciplinary treatment of pediatric solid tumors, specifically pediatric sarcoma of the bone and soft tissue. She also has special interest in pediatric palliative care. Dr. Lagmay participates in several national professional societies and committees, including the Children’s Oncology Group, American Society of Pediatric Hematology and Oncology, American Society of Hematology, Connective Tissue Oncologic Society, and STOP Children’s Cancer. Her practice integrates translational research in targeted radionuclide therapies for osteosarcoma in collaboration with UF Veterinary Medicine, Biomedical Engineering, Chemistry, Material Science Engineering and Radiation Oncology. Her direct collaboration with pediatric oncology colleagues in Florida has resulting phase I clinical trials for pediatric cancer patients in the state. Dr. Lagmay came to UF in 2009 from Nationwide Children’s Hospital, The Ohio State University where she was a fellow in pediatric hematology/oncology. She did her pediatric residency training at the Children’s Hospital of Monmouth in New Jersey, where she also served as chief resident.
Accomplishments
Excellence in Medical Student teaching
2011-2009
·
unknown
Outstanding Achievement for Medical Student Education
2010-2011
·
unknown
Physician Customer Service Recognition
2009
·
unknown
Teaching Profile
Courses Taught
2018
MDC7400 Pediatric Clerkship
2018
MDC7401 Senior Pediatric Clk
2018
MDT7400 Elect Top/Pediatrics
Board Certifications
-
Pediatric Hematology/OncologyAmerican Board of Pediatrics
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Hospice and Palliative Medicine
- Pediatrics
Subspecialties
- Pediatric Hematology-Oncology
Areas of Interest
- Adult soft tissue sarcoma
- Bone tumor
- Ewing sarcoma
- Gynecological cancer
- Head and Neck Cancer
- Neuroblastoma
- Osteosarcoma
- Renal cell carcinoma
- Rhabdomyosarcoma
- Wilms Tumor
Publications
2024
Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.
Cancer journal (Sudbury, Mass.).
30(3):133-139
[DOI] 10.1097/PPO.0000000000000714.
[PMID] 38753746.
2024
Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas.
Scientific reports.
14(1)
[DOI] 10.1038/s41598-024-61651-w.
[PMID] 38811642.
2023
“It Becomes a Family I’m a Part of…We Get to Carry Each Other”: Themes from Qualitative Interview of Patients Enrolled in an Inpatient Palliative Care Support Program for Adolescents and Young Adults.
Journal of palliative medicine.
26(9):1207-1216
[DOI] 10.1089/jpm.2022.0482.
[PMID] 37352414.
2023
A Novel Palliative Care Peer Support Program for Adolescents and Young Adults: Survey and Factor Analytic Study.
Journal of palliative medicine.
26(5):627-636
[DOI] 10.1089/jpm.2022.0299.
[PMID] 36472550.
2023
A pilot study evaluating the use of sirolimus in children and young adults with desmoid-type fibromatosis.
Pediatric blood & cancer.
[DOI] 10.1002/pbc.30466.
[PMID] 37283290.
2023
Microfluidics-Enabled Isolation and Single-Cell Analysis of Circulating Tumor Cells.
Methods in molecular biology (Clifton, N.J.).
2689:71-93
[DOI] 10.1007/978-1-0716-3323-6_7.
[PMID] 37430048.
2020
Chordoma of the Clivus and Acute Myeloid Leukemia: Is There a Connection?
Journal of Pediatric Hematology/Oncology.
42(7):E662-E664
[DOI] 10.1097/MPH.0000000000001659.
2020
Malignant round cell tumor with SS18-POU5F1 fusion: is it a myoepithelial neoplasm, a synovial sarcoma or a new entity?
Histopathology.
77(4):681-684
[DOI] 10.1111/his.14171.
[PMID] 32516451.
2020
Primary mediastinal infantile fibrosarcoma: An unusual presentation involving the thymus.
Pediatric blood & cancer.
67(11)
[DOI] 10.1002/pbc.28402.
[PMID] 32735378.
2020
Primary pulmonary artery sarcoma in the pediatric patient: Review of literature and a case report.
Radiology case reports.
15(7):1110-1114
[DOI] 10.1016/j.radcr.2020.05.016.
[PMID] 32477441.
2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Sarcoma.
2020
[DOI] 10.1155/2020/7935475.
[PMID] 32398945.
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology.
12(1)
[DOI] 10.1186/s13045-019-0756-z.
[PMID] 31311607.
2019
Radiation Treatment for Ewing Sarcoma Family of Tumors in Adult Patients: A Single Institution’s Experience Over 40 Years.
American journal of clinical oncology.
42(5):421-425
[DOI] 10.1097/COC.0000000000000532.
[PMID] 30883389.
2016
Left Ventricular Metastasis in Neuroblastoma: A Case Report.
Journal of pediatric hematology/oncology.
38(1):74-7
[DOI] 10.1097/MPH.0000000000000439.
[PMID] 26479997.
2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children’s Cancer Group, Pediatric Oncology Group, and Children’s Oncology Group: Learning From the Past to Move Forward.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
34(25):3031-8
[DOI] 10.1200/JCO.2015.65.5381.
[PMID] 27400942.
2014
Advances in therapy for pediatric sarcomas.
Current oncology reports.
16(8)
[DOI] 10.1007/s11912-014-0395-z.
[PMID] 24894064.
2014
Synthesis of polymeric phosphonates for selective delivery of radionuclides to osteosarcoma.
Cancer biotherapy & radiopharmaceuticals.
29(7):273-82
[DOI] 10.1089/cbr.2014.1615.
[PMID] 25111903.
2011
Adjuvant radiotherapy for pediatric and young adult nonrhabdomyosarcoma soft-tissue sarcoma.
International journal of radiation oncology, biology, physics.
81(1):150-7
[DOI] 10.1016/j.ijrobp.2010.05.005.
[PMID] 21550181.
2011
Chest wall Ewing sarcoma family of tumors: long-term outcomes.
International journal of radiation oncology, biology, physics.
81(1):158-66
[DOI] 10.1016/j.ijrobp.2010.04.066.
[PMID] 20732765.
2011
External-beam radiotherapy for pediatric and young adult desmoid tumors.
Pediatric blood & cancer.
57(3):435-42
[DOI] 10.1002/pbc.22916.
[PMID] 21744472.
2009
Clear cell sarcoma of the stomach.
Pediatric blood & cancer.
53(2):214-6
[DOI] 10.1002/pbc.22014.
[PMID] 19350639.
2009
Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient.
Journal of pediatric hematology/oncology.
31(5):330-2
[DOI] 10.1097/MPH.0b013e3181979c5e.
[PMID] 19415011.
2009
Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor).
Clinical cancer research : an official journal of the American Association for Cancer Research.
15(16):5234-9
[DOI] 10.1158/1078-0432.CCR-08-2953.
[PMID] 19671870.
2007
Familiarity of pediatricians with different commercially available neonatal and infant formulas.
Clinical pediatrics.
46(5):418-23
[PMID] 17556738.
1999
Cytopathogenicity of Acanthamoeba isolates on rat glial C6 cell line.
The Southeast Asian journal of tropical medicine and public health.
30(4):670-7
[PMID] 10928358.
Grants
Jun 2023
ACTIVE
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma
Role: Principal Investigator
Funding: PENNSYLVANIA STATE UNIV
via Y-MABS THERAPEUTICS INC
Jun 2023
ACTIVE
Adapting the Healthy Communication Practice Program for Parent Caregivers of Adolescents and Young Adults (AYAs) Living with a Blood Cancer
Role: Co-Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Apr 2023
ACTIVE
Towards liquid biopsy for pediatric sarcoma
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jul 2022
– Feb 2024
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma
Role: Principal Investigator
Funding: ERGOMED PLC
via K-GROUP BETA
Apr 2022
ACTIVE
Point-of-care intervention to address financial toxicity in families facing pediatric cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Nov 2021
– Jul 2023
AOST-2121, Protocol OST31-164-01, An Open-Label Phase 2 Study of Maintenance Therapy with OST31-164 After Resection of Recurrent Osteosarcoma.
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via OS THERAPIES
Nov 2021
– Sep 2022
Phase ? Study of Bempegaldesleukin in combination with Nivolumab in Children, Adolescents, and young Adults with Recurrent or Refractory Malignancies
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Jun 2021
ACTIVE
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albuminbound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation
Role: Principal Investigator
Funding: AADI BIOSCIENCE
Feb 2021
ACTIVE
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via FL DEPT OF HLTH LIVE LIKE BELLA
Feb 2021
ACTIVE
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL PEDIATRIC CANCER FOU
Dec 2020
ACTIVE
NMTT- Neuroblastoma Maintenance Therapy Trial Using
Difluoromethylornithine (DFMO)
Role: Principal Investigator
Funding: ATRIUM HEALTH
Nov 2019
ACTIVE
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL PEDIATRIC CANCER FOU
Nov 2019
– Jun 2023
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via FL DEPT OF HLTH
Jul 2019
– Jun 2022
UF Health Cancer Center Pilot Projects funded by UF Foundation Allocated Funds
Role: Project Manager
Funding: UF FOUNDATION
Jul 2018
– Jul 2023
A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease
Role: Principal Investigator
Funding: Y-MABS THERAPEUTICS INC
May 2017
– May 2022
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
Jul 2012
– Jun 2016
A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan and Temozolomide in Chidlren with RElapsed or Refractory Solid Tumors
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via PEDIATRIC CANCER RESEARCH FOU
Education
Residency – Pedicatric Hematology/Oncology
2009
·
Nationwide Children's Hospital
Residency – Pediatrics
2006
·
Children's Hospital at MonMouth Medical Center
Medical Degree
2002
·
University of the Philippines
Contact Details
Phones:
- Business:
- (352) 273-9120
Emails:
- Business:
- jplagmay@peds.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100296
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD HD204
GAINESVILLE FL 32610